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Aims Macrophages in atherosclerotic plaques secrete YKL-40. We tested the hypothesis if high serum YKL-40 concen-
tration predicts coronary events and death of patients with stable coronary artery disease (CAD).
Methods
and results
During the 2.6 years follow-up period (median 2.77 year, interquartile range 0.23 year), 270 patients among the 4298
patients with stable CAD in the CLARICOR trial suffered myocardial infarction (MI) and 377 died (187 classified as
cardiovascular death). Serum YKL-40 transformed as Y¼log[max(82, serum YKL-40/mg/L)] was significantly associ-
ated with cardiovascular death [hazard ratio (HR) ¼ 1.88, 95% confidence interval (CI) ¼ 1.54–2.31, P, 0.001], all-
cause mortality (HR ¼ 2.01, 95% CI ¼ 1.75–2.31, P, 0.001), and MI (HR ¼ 1.38, 95% CI ¼ 1.13–1.68, P ¼ 0.002).
Following multivariable adjustment for cardiovascular risk factors (age, sex, previous MI, smoking status, hypertension,
diabetes mellitus) and selected medical treatments Y contributed significantly to prediction of all-cause mortality
(P, 0.001) and cardiovascular mortality (P ¼ 0.001), but not MI (P ¼ 0.25).
Conclusion High serum YKL-40 is associated with MI, cardiovascular and all-cause mortality in patients with stable CAD.
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Introduction
Circulating levels of YKL-40 is a potential biomarker of acute and
chronic inflammation and tissue remodelling,1–7 including systemic
low-grade inflammation8 and YKL-40 may participate in the innate
immune response.2 YKL-40 is regarded as an acute phase protein,
since its plasma concentration is increased in inflammatory dis-
eases.1–5 YKL-40 is a phylogenetically highly conserved chitin-,
heparin-, and collagen-binding protein with homologues in
vertebrates and invertebrates, and is a member of ‘mammalian
chitinase-like proteins’.3,9
The full biological functions of YKL-40 are unknown. YKL-40 is a
growth factor for fibroblasts10 and has an anti-catabolic effect pre-
serving extracellular matrix during tissue remodelling.11 YKL-40
stimulates migration and adhesion of endothelial cells and
vascular smooth muscle cells (VSMCs), suggesting a role in angio-
genesis,12–14 and may play a role in regulating response of cancer
cells to hypoxia.15 Atherosclerotic plaque macrophages express
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YKL-40, particularly macrophages that have infiltrated deeper into
the lesion, and the highest YKL-40 mRNA expression is found in
macrophages in the early atherosclerotic lesion.16
Studies have suggested that high serum YKL-40 levels could be a
prognostic biomarker of short survival. This is demonstrated in
80-year-old people8 and in patients with Streptococcus pneumoniae
bacteraemia,1 and local or metastatic cancer.7 Serum YKL-40 levels
are elevated in patients with acute myocardial infarction (MI)17,18
and stable coronary artery disease (CAD),19 and associated with
the number of diseased vessels assessed by coronary
angiography.19
In the present study, we tested the hypothesis that elevated
serum YKL-40 is a risk factor for acute coronary syndrome and
death in patients with stable CAD.
Methods
Patients
The patients were included in the randomized, placebo-controlled,
multi-centre CLARICOR trial of patients with stable CAD treated
for 2 weeks with oral clarithromycin 500 mg once daily (Klacid
Unow, Abbott, UK) or a matching placebo.20 The patients had a diag-
nosis of MI or angina pectoris (AP) (ICD codes 209–219), percuta-
neous transluminal coronary angioplasty, or coronary bypass surgery
during the years 1993–99. Exclusion criteria included MI or unstable
AP within the previous 3 months, percutaneous transluminal coronary
angioplasty or coronary bypass surgery within the previous 6 months,
New York Heart Association class IV cardiac failure, impaired renal or
hepatic function, or cancer. In this study, 4373 patients were random-
ized between 5 October 1999 and 15 April 2000; 4350 patients
donated blood and serum was available for YKL-40 determination in
4298 patients.
Follow-up
The patients had a 2.6 years follow-up period (median 2.77 years,
interquartile range 0.23 year). Information about fatal and non-fatal
admissions came from the Danish National Hospital Register, a data-
base of all somatic hospital admissions. Information about death
came from the Danish Central Civil Register, which records the vital
status of all inhabitants in Denmark. Registration is 100% in these reg-
isters. On the basis of these registers, the coordinating centre col-
lected death certificates and copies of hospital records during the
follow-up period and forwarded each potential event separately to
the event committee. As the observed event rate was lower than esti-
mated, the steering committee extended the follow-up period from 2
to 3 years without analysing the data. Final data were collected April
2003.20
Outcomes
In the present study, we examined time from randomization to
re-admission for: (1) unstable AP, (2) MI, (3) cardiovascular death,
and (4) any death. We used pre-specified outcome flowchart forms
to search for possible outcomes. Two randomly chosen members of
the event committee, which consisted of three cardiologists, evaluated
copies of hospital records and death certificates. In case of disagree-
ment between the two evaluations, both forms together with copies
of the record of the event were given to the third member, who
had to select the most likely option. In cases with inadequate infor-
mation, we classified the cause of death as unknown. If sufficient
information was available, we judged death to be due to cardiovascular
disease unless a non-cardiovascular cause was present. In the flow-
chart, the evaluation was performed in concordance with the inter-
national form of medical certificate of cause of death after The
Manual of the International Statistical Classification of Diseases, Injuries
and Causes of Death (World Health Organisation. Manual of the inter-
national statistical classification of diseases, injuries and causes of death.
9th revision. Geneva: WHO, 1974). The potential classification codes
(and the corresponding ICD10 codes) were: acute MI (I21), revascular-
ization due to AP (I20), heart failure (I50), cerebrovascular disease
(I63), and other cardiovascular disease (i.e. I10–I79 except for the pre-
vious mentioned).
Long-lasting chest pain or chest pain at rest without major changes
in cardiac enzymes (creatine kinase-isoenzyme MB or troponin) was
classified as unstable AP. An elevation of cardiac enzymes and signifi-
cant ST changes in the electrocardiogram consistent with myocardial
ischaemia or MI were classified as MI.20
Ethics
The trial was approved by the regional Ethics Committee (KF 01-076/
99), the Danish Medicines Agency (2612-975), and the Danish Data
Protection Agency (199-1200-174), registered at ClinicalTrials.gov
(NCT00121550) and conducted according to the Declaration of Hel-
sinki. Participants gave written informed consent.
YKL-40 analysis
Serum concentrations of YKL-40 were determined in duplicates by a
commercial ELISA (Quidel, San Diego, CA, USA) using streptavidin-
coated microplate wells, a biotinylated-Fab monoclonal capture
antibody, and an alkaline phosphatase-labelled polyclonal detection
antibody. The recovery is 102%, detection limit 20 mg/L, intra-assay
coefficient of variation (CV) , 5.0%, and inter-assay CVs are ,5.4%
(low control) and ,6.7% (high control) in the 127 ELISA kits used
for the analysis of the 4298 samples.
Statistical analysis
Cox-analyses were used to analyse the effect of one or more
covariates on the time to an event. Extended Cox analyses including
a covariate, time, and the interaction between time and the covari-
ate as variables was used to test the proportionality assumption of
the Cox model. The latter test was supplemented by a visual assess-
ment of the log–log plots of the groups of the covariate. The
assumption of the Cox model of linearity between a continuous
covariate and the logarithm of the hazard ratio (HR) was assessed
from an inspection of the relationship between the log HR and
the mean value of the groups defined by the deciles of the covari-
ate’s distribution.
The proportionality assumption of the Cox model was fulfilled for
all four events. The assumption for the Cox model of linearity
between serum YKL-40 and the logarithm of the HR was not fulfilled
in any of the analyses. Since there was no relationship between serum
YKL-40 and the log of the HR of any of the events at serum YKL-40
levels below 82 mg/L and a linear relationship between the log of
YKL40 and log HR above this value, we transformed serum YKL-40
using the transformation: Y¼log[max(82, serum YKL-40/mg/L)]. Age
fulfilled the linearity assumption in case of the events all-cause death
and cardiac death. For MI the transformation Y¼max(63, age/year)
was used.
If transformed serum YKL-40 had a significant effect on the time to
an event, we repeated the analysis adjusting for the known risk factors
(age, sex, previous MI, smoking status, hypertension, diabetes mellitus).
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If the effect was still significant, we included selected indicators of
treatment in the analysis. These factors were selected as follows: A
random sample comprising one-half of the patients was selected and
an analysis of the corresponding data material including as covariates
the risk factors and all indicators of medical treatment (beta-blocker,
ACE-inhibitor, calcium blocker, statin, magnyl, long-lasting nitrates,
digoxin, diureticas, anti-arrhythmicas) was done. In this analysis, all cov-
ariates except the treatment indicators were forced to stay in the
analysis which comprised a backward elimination using the likelihood
ratio test with P ¼ 0.10 for removal of variables. The analysis was
repeated using the other half of the data material. The treatment indi-
cators selected were those that were retained in both of these two
analyses. In all analyses the intervention indicator was forced to be
included in the model.
Since the distributions of serum YKL-40 as well as those of log
(YKL-40) differed significantly from the Gaussian distribution as
assessed by the Shapiro–Wilk W test, non-parametric tests (Mann–
Whitney test) were used to compare serum YKL-40 levels between
patient groups.
The level of significance used was 0.05 and all tests were two-sided.
To account for the inflation of the experiment wise Type I error due
to multiple testing, we used the Bonferroni correction giving a
significance level of 0.05/22¼0.0023 since 22 tests were done. The
analyses were done using the SPSS version 15.0.
Results
Serum YKL-40 in relation to
demographic and clinical characteristics
of the patients with stable coronary
artery disease
The demographic data and the relationship between serum con-
centrations of YKL-40 and the demographic data of the 4298
patients with stable CAD are described in Table 1. The median
serum YKL-40 was 110 mg/L (range 20–3047 mg/L). Serum
YKL-40 was higher in patients with age .60 years, diabetes, hyper-
tension, and in patients treated with calcium-antagonist,
ACE-inhibitors, long-lasting nitrates, diuretics, and digoxin com-
pared with patient without (Table 1). In contrast, patients treated
with statin and magnyl had lower serum YKL-40 compared with
untreated patients (Table 1).
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Table 1 Serum YKL-40 concentrations (mg/L, given as median and 25th and 75th percentiles) in the patients with stable
coronary artery disease according to demographic, clinical, and medical characteristics
Quantities n Median 25 percentile 75 percentile P-value of difference
Sex Males 2985 111 75 169 0.77
Females 1313 109 77 166
Age 60 year 3016 119 82 180 ,0.001
,60 years 1282 92 64 135
Diabetes Yes 661 124 85 195 ,0.001
No 3637 108 75 163
Hypertension Yes 1731 116 79 179 ,0.001
No 2567 106 73 160
Smoking habits Smoker 1545 112 78 172 0.022
Non-smoker 2753 107 74 166
Previous MI Yes 2914 111 77 170 0.04
No 1384 106 73 163
Magnyl Yes 3778 109 75 166 0.003
No 520 116 82 189
Beta-blocker Yes 1314 108 75 164 0.28
No 2984 111 76 170
Calcium antagonist Yes 1503 113 78 177 0.009
No 2795 108 74 164
ACE-inhibitor Yes 1159 118 78 177 0.001
No 3139 107 75 164
Long-lasting nitrates Yes 902 121 85 189 ,0.001
No 3396 107 73 163
Diuretics Yes 1506 128 86 194 ,0.001
No 2792 102 73 86
Digoxin Yes 275 139 97 211 ,0.001
No 4023 108 75 166
Statin Yes 1768 102 72 151 ,0.001
No 2530 116 79 177
Anti-arrhythmicas Yes 101 123 84 203 0.11
No 4197 110 75 167
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Serum YKL-40 as predictor of unstable
angina pectoris, myocardial infarction,
cardiovascular death, and all-cause
mortality in patients with stable coronary
artery disease
During the 2.6 years follow-up, a new unstable coronary syndrome
event occurred in 373 patients (8.7%), including 120 patients with
unstable AP (2.8%) and 270 with MI (6.3%). Seventeen patients
were registered with both unstable AP and MI (0.4%). In the
entire population a total of 384 died, 189 (49.2%) had a cardiovas-
cular death, 77 (20.1%) died due to cancer, 84 (21.9%) died from
other causes (e.g. pneumonia, sepsis, chronic obstructive pulmon-
ary disease, and asthma), and 34 (8.9%) died from unknown cause.
One hundred and thirty-three patients died in hospital and 251
died before being admitted to hospital. In the YKL-40 study popu-
lation 187 patients suffered cardiovascular death (4.4%) and a total
of 377 patients died (8.8%).
Y (the transformed serum YKL-40) was significantly associated
with cardiovascular death [HR ¼ 1.88, 95% confidence interval
(CI) ¼ 1.54–2.31, P, 0.001], all-cause mortality (HR ¼ 2.01,
95% CI ¼ 1.75–2.31, P, 0.001), and MI (HR ¼ 1.38, 95% CI ¼
1.13–1.68, P ¼ 0.002), but not unstable AP (P ¼ 0.85) (Table 2).
Following multivariable adjustment for cardiovascular risk factors
(age, sex, previous MI, smoking status, hypertension, diabetes mel-
litus) Y contributed significantly to the prediction of all-cause mor-
tality (HR ¼ 1.67, 95% CI ¼ 1.43–1.95, P, 0.001) and
cardiovascular mortality (HR ¼ 1.51 95% CI ¼ 1.20–1.89, P ¼
0.001), but not MI (P ¼ 0.26) (Table 2). In the analysis where the
predictive significance of medical treatments was assessed while
all risk factors were forced to remain in the analysis (see section
on Statistical analysis), treatment with diuretics, digoxin, and
statin were retained in the analysis of time to death. In the analysis
of time to cardiovascular death, only treatment with digoxin was
retained, and in the analysis of time to MI only ACE-inhibitor
was retained. Following multivariable adjustment for cardiovascular
risk factors and the selected medical treatment indicators
Y contributed significantly to prediction of all-cause mortality
(HR ¼ 1.62, 95% CI ¼ 1.37–1.90, P, 0.001) and cardiovascular
mortality (HR ¼ 1.52, 95% CI ¼ 1.20–1.92, P ¼ 0.001) (Table 2).
For illustrative purposes, we show the event-free survival for
unstable AP, MI, cardiovascular death, and all-cause mortality
during the 2.6 years of follow-up for six serum YKL-40 groups in
Figure 1A–D.
Discussion
We observed that high serum YKL-40 is a significant predictor for
cardiovascular death, all-cause mortality, and MI in patients with
stable CAD. Correcting the analyses for risk factors and selected
medical treatments had a moderate impact on the HRs for all-
cause mortality and cardiovascular death, but eliminated the
relation to MI. High serum YKL-40 was not associated with
unstable AP, however the number of these patients was small.
The strengths of the present study are the size of the patient
population, no losses to follow-up of events, and the ethnic homo-
geneity of the patient population. A weakness is that only serum
YKL-40 was determined and not other potential prognostic bio-
markers of MI and death in patients with CAD, e.g. C-reactive
protein and B-type natriuretic peptide (BNP).21–26 In patients
with stable CAD, the highest serum NT-pro-BNP level had an
HR of 2.4 for all-cause mortality,22 and the highest serum CRP
level had an HR for cardiac death of 1.75, and for all-cause mor-
tality of 1.78 during a 4.8 years follow-up period.23 In the
WIZARD trial including 3319 patients with stable CAD treated
with azithromycin or placebo using serum CRP as a biomarker,
the HR for all-cause mortality was 2.18 in the 3.1 years follow-up
period.24 In the present study, with a shorter follow-up (2.6 years),
the HRs using serum YKL-40 as a biomarker were 1.38 for MI, 1.88
for cardiovascular death, and 2.01 for all-cause mortality. Due to
differences in study populations, a direct comparison of HRs
between different biomarkers in published studies is not valid.
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Table 2 The effect of f(YKL-40)a on time to death, to cardiovascular death, and myocardial infarction alone or in
combination with risk factors and risk factors plus selected indicators of treatment









HR 95% CI P-value HR 95% CI P-value HR 95% CI P-value
Death 2.01 1.75–2.31 ,0.001 1.67 1.43–1.95 ,0.001 1.62 1.37–1.90 ,0.001
Cardiovascular death 1.88 1.54–2.31 ,0.001 1.51 1.20–1.89 ,0.001 1.52 1.20–1.92 0.001
Myocardial infarction 1.38 1.13–1.68 0.002 1.13 0.91–1.41 0.26 1.14 0.91–1.41 0.25
HR, hazard ratio; CI, confidence interval.
af(YKL-40)¼log[max(82, serum YKL-40/mg/L)].
bIndicator of treatment with clarithromycin included a priori in all analyses (reference: placebo).
cAge, sex, hypertension, diabetes, smoking habits, and previous myocardial infarction.
dTreatment indicators for diuretics, digoxin, and statins were included in the analysis of death. In the analysis of cardiovascular death only the indicator of digoxin treatment was
included. In the analysis of myocardial infarction only that of ACE-inhibitor treatment was included.
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Since risk factors such as BMI, renal status, as well as other poten-
tial biomarkers were not measured in the present study the signifi-
cance of serum YKL-40 in the prediction of all-cause death
combined with those risk factors examined in the study by
Pencina et al.27 cannot be meaningfully assessed. Future studies
with all relevant risk factors included should evaluate whether
serum YKL-40 provide substantially better prediction of all-cause
mortality in patients with stable CAD than that obtained using
all known and relevant risk factors alone.
Our results suggest that serum YKL-40 could be a new bio-
marker of acute and chronic inflammation in patients with stable
CAD. Circulating YKL-40 may reflect the total burden of coronary
atherosclerosis or identify a high-risk atherosclerosis phenotype
with ongoing inflammation and atherosclerotic plaque formation.
The molecular processes governing the induction of YKL-40 and
its precise biological functions are unknown. In contrast to CRP,
mainly produced by hepatocytes in response to high IL-6,
YKL-40 is produced by macrophages and neutrophils in tissues
with inflammation2,3,5,16,28 and by differentiated macrophages and
activated neutrophils.29,30 Interestingly, macrophages in athero-
sclerotic plaques express YKL-40 mRNA, particularly macrophages
located deep in the lesion, and the highest YKL-40 expression is
found in macrophages in the early lesion of atherosclerosis.16
YKL-40 is also synthesized by VSMCs and promotes their
migration and attachment,12–14 suggesting a role in the process
of atherosclerotic plaque formation, where VSMCs are induced
to migrate through the intima in response to exogenous signals.
In vitro YKL-40 is synthesized by swine VSMCs isolated from the
thoracic aorta during the time of transition from a proliferating
monolayer culture to a non-proliferating differentiated multilayer
culture, and YKL-40 secretion continued as VSMCs reorganize
and differentiate.12–14 This nodule forming process mimics some
of the characteristics of the in vivo changes that occur in VSMCs
following injury, where media SMCs dedifferentiate, migrate, and
Figure 1 Event-free survival for (A) unstable angina pectoris, (B) myocardial infarction (MI), (C) cardiovascular death, and (D) all-cause
mortality during 2.6 years of follow-up of each of six serum YKL-40 groups. YKL-40 , 110 mg/L (blue), 110 mg/L  YKL-40 , 129 mg/L
(green), 129 mg/L  YKL-40 , 153 mg/L (black), 153 mg/L  YKL-40 , 191 mg/L (dark green), 191 mg/L  YKL-40 , 256 mg/L (pink), and
256 mg/L  YKL-40 (red). These groups were formed by first dividing the serum YKL-40 levels into 10 groups using the deciles of the
serum YKL-40 distribution. Then the first five of these groups were combined into one to obtain in all the above six groups.
J. Kastrup et al.1070






contribute to the process of vascular restenosis and neointima for-
mation. Furthermore, YKL-40 modulates vascular endothelial cell
morphology by promoting the formation of branching tubules,
indicating a role in angiogenesis by stimulating the migration and
reorganization of vascular endothelial cells.13,14
However, some of the circulating YKL-40 in our group of
patients with CAD who died of cancer during follow-up, may
have originated from cancer cells.7 Since YKL-40 is not disease
specific co-morbidity should always be considered, and it has
recently been found that elevated plasma YKL-40 predicted
increased risk of gastrointestinal cancer in the general population.31
Serum YKL-40 is increased up to seven-fold in both
patients with stable CAD and after an acute ST-elevation MI
(STEMI)17–19 and associated with the number of angiographically
demonstrated coronary artery stenosis.19 This supports the
hypothesis, that YKL-40 plays a role in both the acute inflammatory
process eliciting or responding to protect against the plaque
instability and in the recovery and remodelling process after an
acute STEMI by promoting the growth of new cardiomyocytes
and inducing angiogenesis. YKL-40 may protect cardiomyocytes
from undergoing apoptosis under ischaemia, since YKL-40
expression is up-regulated in cancer cells following hypoxia.32 It
has to be demonstrated in future studies, whether serum
YKL-40 will fulfil the three fundamental requirements to be a
potentially useful new biomarker: (1) analytical methods that
allow reliable measurement are available to every clinician; (2)
provide prognostic information in multiple studies and diverse
populations, with incremental prognostic information when
added to validated risk scores; and (3) help the clinician to
manage patients.33 Only requirement (1) is fulfilled at present,
since we used a commercially available YKL-40 ELISA. This
method takes less than 4 h, has low intra- and inter-assay coeffi-
cients of variation, and the intraclass correlation coefficient indi-
cated reasonable reliability of serum YKL-40 measurements and
relatively small variation in healthy subjects.34
In conclusion, serum YKL-40 was found to be a biomarker for
MI, cardiovascular death, and all-cause mortality in patients with
stable CAD. The mechanism(s) involved cannot be resolved
from the present study and has to be clarified in future studies.
We speculate if serum YKL-40 could be used for monitoring the
sufficiency of medical treatment of patients with stable CAD and
thereby assist in the reduction of the high occurrence of non-fatal
and fatal cardiovascular events in these patients.
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